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 Early neuroimmune dysfunction may play a pivotal role in the etiopathology of Alzheimer’s 
disease (AD), as it is hypothesized that many late-stage adult diseases have an early-life basis.  Here we 
explore whether exposure to a known neuroimmunotoxicant during a period of developmental 
susceptibility in the central nervous system (CNS) parenchyma exacerbates the pathologies in an AD 
prone triple transgenic mouse model (3xTgAD).  This “double-hit” research design modeled the high 
variability in AD due to detrimental exogenous influences, rather than the minority of AD cases that 
have a well-defined genetic origin and regular neurodegenerative progression.  Triple transgenic mice 
were treated by gavage with lead acetate from postnatal day 5-15, a critical developmental window for 
microglia, immune cells of the CNS that are thought to play a major role in shaping the CNS. Microglial 
phenotype and colocalization with amyloid-β, the protein associated with AD senile plaques, were 
analyzed to detect changes in pathological severity.  Our data indicate that early exposure to a 
neurotoxicant increases the number of activated microglia with age, which we hypothesize is due to 
either degradation of homeostatic inhibitory signaling pathways associated with early onset synaptic 
degeneration or over-burdened microglial phagocytic load. Furthermore, microglial activation states 
differed between genders and fluctuated with age, suggesting a sex-specific component to AD pathology 
 
 
and potential correlation of neurodegenerative diseases with hormone receptors in the sexual 
differentiation of the developing brain. 
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Chapter 1: 
Introduction 
 
 The potential implications of developmental immunotoxicity in the etiopathology of 
neurodegenerative disorders, such as Alzheimer’s disease (AD), have recently become an exciting area 
of biomedical research.  Many adult diseases are now being linked to early-life disturbances of the 
delicate immune balance induced by environmental insults.  Our primary research utilized this 
hypothesis as scaffolding to elucidate the role of exposure to a neuroimmunotoxicant.  We evaluated 
the potential impact of immune dysfunction induced by exposure to a neuroimmunotoxicant during a 
critical period of neuroimmune development on AD pathology and disease progression in a genetically 
susceptible model of AD.  While there may be considerable variability in environmental agents that have 
the ability to influence AD pathologies, we specifically chose the neurotoxic metal lead acetate due to its 
activating effects on microglia, the resident immune cells of the brain. 
To ensure that pathologic conditions would be present, we used a triple transgenic mouse 
model for AD (3xTgAD).  This particular model develops signs of AD neuropathologies (i.e. “plaques and 
tangles”) as early as three to six months of age (www.jax.org).  By exposing this AD model to lead during 
postnatal development we were able to model the genetic and environmental interface of subsets of 
human AD patients.  We anticipate that evaluation of early-life vulnerabilities for AD will result in a 
better understanding of the highly complex etiologies of neurodegenerative disorders. 
Developmental Immunotoxicity  
 Exposure to environmental toxicants early in development may lead to systematic changes to 
the highly regulated immune network, potentially persisting to, and causing stress in, adulthood (Leifer 
and Dietert, 2011).  The compromised immune system is then unable to effectively maintain its 
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homeostatic mechanisms and inadvertently contributes to the exacerbation of adult diseases.  There 
appears to be a fairly pervasive underlying motif in the toxicological literature that a developing immune 
system will have higher vulnerability to a toxicological agent than its fully matured and competent adult 
counterpart lacking the equivalent array of critical windows (Dietert, 2011).  The increased sensitivity 
during these developmental critical periods can be attributed to fluctuation in immune parenchymal 
activity, differentiation, and extensive reliance on highly dynamic, yet strict signaling pathways.  This 
minimal tolerance of temporal and spatial variability during these periods of vulnerability presents the 
opportunity for highly specific toxicological investigation into a developmental event of interest (DeWitt 
et al., 2012).  Developmental immunotoxicity (DIT) evaluation frequently employs these critical 
windows, as well as the full pre- and neonatal maturational continuum, for risk assessment with high 
developmental specificity and accuracy (Dietert and DeWitt, 2010). 
 Exogenous agents considered immune-disruptive can have an assortment of impacts on the 
immune system, including over-excitation, suppression, and general homeostatic imbalance.  Because 
we are focusing on “toxic” agents we often make the assumption that physiological change is adverse.  It 
is important, also, to consider the structural, as well as functional, changes that occur, as not all 
deviations from a typical immune baseline present the same way (DeWitt et al., 2012).   
Immune disruption has been linked to a wide assortment of disease states, varying from 
autoimmune/inflammatory diseases to cancer.  Moreover, a new research front is emerging that 
implicates disrupted immune systems in neurodegenerative disease pathologies.  AD, for example, is 
generally considered an inflammatory disease due to the severe “neuroinflammation”-induced release 
of proinflammatory signals, including cytokines, chemokines, proteases, and activated complement 
proteins by activated microglia (Lue et al., 2010).  However, neuronal inflammation and neurotoxicity 
differ drastically from peripheral inflammation, which is why many neuropathologists adamantly refute 
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the all-encompassing “neuroinflammatory” nomenclature (Richartz, et al., 2005).  Aguzzi et al (2013) go 
so far as to say neuroinflammation is not inflammatory at all, but instead degenerative, due to the 
restricted activation of microglia instead of the conventional inflammatory cascade.  Neuroinflammation 
is generally regarded as deleterious, whereas classical, peripheral inflammation, under appropriate 
circumstances, is a major player as a first line of defense by the immune system.  Peripheral 
inflammation acts to limit the spread of infection, remove debris, and initiate tissue repair.  In one 
sense, neuroinflammation, due to the expression of the MHC-II surface marker on activated microglia 
and attraction of pro-inflammatory cytokines, is a textbook inflammatory response (Lue et al, 2010).  
However, to add yet another layer of complexity to the debate, microglia express two antagonistic 
activation states, pro- or anti-inflammatory, depending on extracellular signaling, and, unlike cells of the 
peripheral immune system, are not known to be divided into different subtypes.  While this argument 
on interpretation may seem capricious and irrelevant, the most heated etiopathological dispute in AD is 
the involvement of microglia and the immune system in the molecular mechanisms of its pathology. 
A common ground in AD research is immune dysfunction in AD, either through excessive pro-
inflammatory signaling or degradation of homeostatic inhibitory signaling.  Regardless of the classical 
definition of inflammation, AD has been correlated with the inflammatory response of the CNS time and 
time again (Leifer and Dietert, 2011).   
Alzheimer’s Disease and Neurodegeneration 
 AD is a chronic, late-onset neurodegenerative disease that presents with myriad hallmark 
pathologies, including extracellular amyloid-β senile plaques, intracellular neurofibrillary tangles 
comprised of a tau protein, gross synaptic and neuritic loss, low cerebral glucose metabolism, and 
abnormal vasculature due to degradation of the blood-brain barrier (BBB).  There is an intimate and 
temperamental relationship between genetic and environmental influences in disease pathogenesis.  
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This interplay of endogenous and exogenous effectors can also be seen in the primary dichotomy of 
Alzheimer’s disease manifestations: familial and sporadic AD.   
Although our research does not directly assess the genetic components of AD, the exploration of 
resultant physiological changes from genetic mutations has the potential to corroborate etiological 
hypotheses.  AD has genetic heterogeneity, meaning mutations in numerous genes result in the same 
pathological phenotype (Pericak-Vance and Haines, 1995).  Although AD has a high degree of mutagenic 
multiplicity, the autosomal dominant transmission involves susceptibilities in four ubiquitous loci: 
Presenilin I, Presenilin II, APOE, and APP (Pericak-Vance and Haines, 1995).  The triple transgenic mouse 
model has mutations in the PS1 (M146V), APP (Swe), and tau (P301L) loci, which mimic a genetic 
predisposition by progressively accumulating senile plaques and neurofibrillary tangles.  Incorporating 
the 3xTgAD model’s overt genetic factors into our study design allows for more concise exploration of 
the environmental influence on AD pathological severity, essentially eliminating the confounding 
ambiguity of potentially unknown genetic influences.  This reasoning is also justification for not including 
a wildtype control group in our experimental design, although future research may utilize such a 
comparison. 
Sporadic AD is far less predictable.  As the name suggests, the disease develops with no 
discernable pattern between individuals lacking typical genetic inheritance, and can differ in both onset 
and severity.  Sporadic AD research is garnering a more intense research focus than its genetic 
counterpart due to the etiologic possibilities and numerous exploratory tangents.  The experiment we 
conducted was designed with the understanding that non-stereotyped progression could be attributed 
to exogenous agents, e.g. neurotoxicants and immunotoxicants.  From this point on we will refer to 
sporadic AD as simply Alzheimer’s disease, as our particular research is aimed at the combination of 
environmental, rather than solely genetic, effects on the exacerbation of AD.   
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Etiopathology  
Discordant hypotheses debating the precise mechanism by which the AD pathologies originate 
implicate a variety of possible culprits, including glial deposition of misfolded proteins, neuritic and 
somal degradation, and global oxidative and lysosomal stress.  Our mechanistic focus, however, is on 
dysfunction of the neuroimmune parenchyma, and impacts on the protein amyloid-β.  We chose not to 
explore the etiology of the tau protein, which accumulates and forms disruptive fibrillary tangles within 
neurons because the triple transgenic murine model (3xTgAD) develops amyloid-β (Aβ) pathologies prior 
to development of neurofibrillary tangles (Oddo et al., 2003b).  Likewise, the conformational changes in 
tau protein are not detectable until about 12 months of age, which was outside of our experimental 
time frame (Oddo et al., 2003a).  This is complementary to the prevailing hypothesis that implicates 
amyloid-β as the primary catalyst for pathogenesis, and, as we are interested in the early stages of 
disease, allows us to disregard tau pathologies in our focused methodology.  
There is moderate evidential support for the neuroinflammation theory, which states that 
neuritic and synaptic deterioration seen in early stage AD has a direct impact on the localized 
inflammatory response (Richartz, et al., 2005).  The triple transgenic mouse model used in our research 
has been shown to exhibit considerable synaptic and neuritic degeneration preceding any detectable 
senile plaque formation or tau neurofibrillary tangles (Oddo et al., 2003a).  However, as previously 
mentioned, the term “neuroinflammation” comes bearing a variety of definitions and implications as to 
the beneficial versus deleterious effect of this non-classical inflammatory response.   
Etiopathogenesis in AD is neither clear-cut, nor well-understood.  However, recent strides 
regarding the very first signs and symptoms of disease have begun to explore the exact sequence of 
events and potential therapeutic targets. 
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Amyloid-β 
A vast majority of researchers subscribe to the Amyloid Cascade Hypothesis (ACH), a molecular 
model for AD etiopathology that states that the catalyst for all other pathologies is the net increase and 
accumulation of both soluble and insoluble amyloid-β.  Recent investigations of the ACH have begun to 
delineate the astounding mechanistic complexity of this highly nuanced disease. 
Amyloid-β is a broad term used for a protein that has the ability to fold in on itself in beta-
pleated sheets, which then self-aggregate, typically in the extracellular environment (Figure 1).  These 
polymers have appeared in a variety of pathological states, including traumatic brain injuries and prion 
diseases (Baglioni et al., 2006).  Amyloid-β can deposit extracellularly as soluble oligomers, protofibrils, 
and insoluble fibrils, the latter of which contribute to senile plaque formation.  As the disease 
progresses, the total amount of amyloid-β over-accumulation is equal to the production and deposition 
of the protein minus its overall clearance.  The imbalance of deposition and clearance stimulates various 
mechanisms for amyloid-β over-accumulation.  One hypothesis associated with over-production 
implicates changes in amyloid precursor protein (APP) secretase activity, the protease involved in APP 
cleavage (Mawuenyega et al., 2010).  However, both familial and sporadic AD have been shown to 
exhibit no significant differences in the length of the dominant protein isoform (Aβ1-42 and Aβ4-42) of 
senile plaques, nor a skew towards isoform dominance (Portelius et al., 2010).  This congruency in 
insoluble isoform could be due to the dysfunctional activation of the unfolded protein response (UPR) in 
the endoplasmic reticulum, which typically reduces the accumulation of misfolded proteins and whose 
upregulation is seen in AD individuals (Hoozemans et al., 2005).  While plaque etiopathological theory is 
an intriguing and highly contested area of research, our own experimental design was created with a 
bias towards early-stage etiologic neuroimmune dysfunction associated with toxicant exposure.  Thus, 
we focus our attention to the primary basis of amyloidogenesis and the associated hypotheses. 
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Large portions of ACH supporters assign low order soluble aβ isoforms with an integral role in 
amyloidogenesis.  The soluble oligomeric form of aβ has been shown to be particularly neurotoxic, 
promoting degradation and ultimate dysfunction at both neuronal synaptic endings and dendritic spines 
(Lambert et al., 1998; Li et al., 2009).  However, a recent study by Watt et al. (2013) has shown that the 
dimerization of aβ can be induced by sodium dodecyl sulphate (SDS), demonstrating that protein 
environment is intimately correlated with its structure, function, and subsequent neurotoxicity.  While 
the soluble isoform may have the capability to be neurotoxic, an umbrella statement implicating low 
order aβ isoforms as the catalyst for AD is at the far end of data extrapolation and should be considered 
as thoroughly context dependent. 
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Figure 1. Molecular mechanism for amyloid-β production and the Amyloid Cascade Hypothesis (ACH). 
BACE1: β-site APP cleavage enzyme-1; APP: amyloid precursor protein; PHFs: paired helical filaments; 
AD: Alzheimer’s disease. (Paolo and Kim, 2011). 
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Neuritic Dysfunction and Synaptic Degradation 
 At the risk of getting lost in theory, we need to take yet another step back to analyze the 
contrasting and varied hypotheses regarding the first signs of Alzheimer’s pathology and molecular 
predisposition to disease.  A fairly encompassing review by Fiala (2007) proposed dystrophic neurites, so 
called for the abnormal shape and indistinguishable typical neuronal structures, as the initiators of 
amyloidosis.  This hypothesis cites the pervasive correlation of axonal damage and plaque formation in a 
variety of disease states (Fiala, 2007).  Where and why the abnormal protein misfolding occurs is still 
under debate, but this review highlights an important vulnerability subject to insult in amyloid 
etiopathogenesis.  The new question, then, is why do patients with AD experience an increase in axonal 
damage, and what role does the immune system play, if any, in these early stages of disease? 
Continuing with a neuritic focus on AD etiopathology, a recent study by Schinder et al (2009) 
demonstrated a reduction in adult hippocampal neurogenesis through impaired inhibitory GABAergic 
signaling, which then increased overall susceptibility to neurodegenerative diseases.  Adult neurogenesis 
is critical for learning and memory in the hippocampus, an area known for marked atrophy in late-stage 
Alzheimer’s (Schinder et al, 2009).  The hippocampus is one of the only two known areas of the brain 
that has the ability to support neuronal regeneration in an adult, which may be why AD presents itself in 
this localized region of high metabolic activity.  We chose to utilize the hippocampus in our study for this 
particular reason, in an endeavor to expose the neuronal vulnerability for amyloidogenesis and the 
potential interface with the immune system. 
There are numerous investigations into the effects of the peripheral and central immune system 
involvement in neurodegenerative disorders.  We chose to focus only on innate CNS neuroimmunity and 
deregulation of normal homeostatic mechanisms that occur independently from the direct actions of 
infiltrating peripheral immune cells due to a breakdown of the blood-brain barrier.  While we cannot 
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discount peripheral immune system involvement in the process that we were trying to model, by 
evaluating neuropathologies relatively early in life, we minimized the impact of peripheral macrophage 
activation, for example, that were unrelated to our specific research aims.  Thus, we chose to 
manipulate the developmental environment with exposure to a model toxicant that is known to affect 
both the immune and nervous systems. 
Neuroimmunotoxicants and the Immune System 
 The search for a potential experimental neurotoxicant able to produce a quantifiable physiologic 
change, and also capable of inducing developmental immunotoxicity, led us to lead.  Our particular 
study had a unique set of demands for a model neuroimmunotoxicant.  Not only did the exogenous 
agent need to be able to cross the blood-brain barrier to produce quantifiable results in the CNS, but the 
effects had to be pertinent to and capable of detecting changes in Alzheimer’s pathologies.   
From a developmental immunotoxic standpoint, lead acetate was an ideal candidate.  Lead 
neurotoxicity has been exhaustively researched following the emergent correlation of exposure with 
cognitive and behavioral deficits in children.  A study by Zurich et al (2002) demonstrated that increased 
uptake and accumulation of lead not only occurred in a developmentally-dependent manner, but also 
had profound effects on neuronal and glial gene expression.  Furthermore, there was marked activation 
of microglia following lead exposure, which could act as a quantitative analytical tool for 
neurodegeneration, inflammation, and amyloid-β accumulation endpoints (Zurich et al, 2002). 
Lead acetate exposure has been linked to upregulation of the APP gene, the innate 
transmembrane protein seen in healthy as well as diseased brains (Basha et al, 2005).   The proteolytic 
cleavage of APP produces two common isoforms of the resultant amyloid-β fragments, Aβ42 and Aβ40, 
referred to collectively as amyloid-β; these insoluble fibrils then readily accumulate and constitute the 
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major component of senile plaques.  The most common isoform, Aβ42, is more frequently associated 
with plaque formation, whereas Aβ40 presents with greater numbers in amyloid angiopathy 
(Mawuenyega et al., 2010).  
Abnormal immune-mediated clearance of protein rather than increased production may also act 
as the source of Aβ over-accumulation.  Disruptions in normal immune recognition, phagocytosis, and 
transport, both via cerebrospinal fluid (CSF) and across the blood-brain barrier, are among a few of the 
most frequently studied processes (Mawuenyega et al., 2010).  CSF transport is an interesting 
hypothesis, which also ties into disruptions in circadian rhythm, seen in late stage AD patients.  An 
increase in CSF movement during the night assists in normal homeostatic processes.  However, these 
individuals have less diurnal and more nocturnal activity, disrupting sleep patterns and normal CSF flow 
(Duncan et al., 2012).  Cerebrospinal fluid transport may have a role in decreased amyloid-β clearance, 
but a study by Duncan et al. (2012) linked this disrupted sleep-wakefulness rhythms to pathologies in 
the hypothalamic suprachiasmatic nucleus.  Future studies may help elucidate the mechanistic link 
between CSF flow and early immune disruption of adult disease. 
A continuation of the deposition vs clearance equation then turns our attention to other forms 
of inherent immune cleanup in the CNS.  Neuroglia are known to provide scaffolding, nutritional 
support, and removal of harmful metabolites and cellular debris.   But how can passive, reactionary glial 
cells protect the brain without help from the circulating immune system?  There is one cell at the 
interface of the nervous system and immune system capable of initiating a full scale attack on a CNS 
insult: microglia. 
Microglia and the Neuroimmune System 
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 The brain and spinal cord are home to microglia, arguably the most interesting and diverse cells 
in the body.  Microglia are the resident immune cells of the CNS; where the immune system and nervous 
system coalesce, there are microglia-exhibiting properties of both.  Thought to originate from the 
mesoderm, the microglia precursors migrate during embryonic and early postnatal stages (Pocock and 
Kettenmann, 2007).  However, the rate at which microglia colonize the developing brain differs with sex.  
Various studies utilizing rat models revealed twice as many microglia with a more active morphology 
early in postnatal development for males, and a parallel, later increase in females during adolescence 
(PND30-60) (Lenz et al., 2013; Schwarz et al., 2012).  Because of this sexual dimorphism during a critical 
window of microglial development we separated males and females within treatment groups for data 
analysis.  After migration, the resident microglia are fully confined within the blood-brain barrier, and 
peripheral, circulating microglia only infiltrate the CNS during highly osmotic or pathologic states 
(Graeber and Streit, 2010).   
 Until a few decades ago, the enormous microglial diversity led many scientists to believe a single 
cell could not encompass all observed morphogenic and functional characteristics, and only a multiple 
cell type model could explain the variety.  Although there is a graded continuum of morphologies, we 
focused on the two extremes: ramified and amoeboid (Figure 2).  Ramified microglia are considered 
dynamic sentinels, and have relatively small somas with long cytoplasmic projections, which are used to 
actively monitor its microenvironment.  Under a light microscope these cells appear most like other 
neuroglia, such as astrocytes, and carry many of the same surface markers.  Likewise, a ramified 
microglial cell will typically perform protective and homeostatic functions in the CNS.  Activated, or 
amoeboid-like microglia, are at the opposite end of spectrum and will exhibit a large, inflamed soma 
with the retraction of its thin projections to aid in motility and release of signaling molecules.  These 
activated microglia can perform a variety of functions, including initiation of the neuroinflammatory 
response, phagocytosis of pathogens, and the excision of superfluous synapses during brain 
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development.  This macrophage-like morphology also mimics macrophage-like function, surface 
antigens, and mobility.  These cells essentially transition from neuroglia to immune cells, depending on 
the variety of microenvironmental signals they receive. 
 While neuronal cross-talk and molecular signals dictate much of the microglial response, there 
are two generally accepted forms of activation (Figure 3).  The M1 state, or classical activation state, is 
considered proinflammatory, characterized by production of cytokines, chemokines, prostaglandins, and 
toxic intermediates, as well as antigen-presentation capabilities (Selenica et al., 2013).  The M2 state, or 
alternative activation, is associated with increased production of IL-4, IL-10, and TGF-β, all neurotrophic 
in nature (Selenica et al., 2013).  Another way to define these states of activation could be neurotoxic 
(M1) versus neuroprotective (M2).  Both states are highly regulated by neuroenvironmental signaling, 
complicating any pathological association.  Irregularities can occur virtually anywhere; neurotoxicity may 
dominate due to over-activation of the M1 state, or perhaps lack of appropriate meta-regulation of the 
M2 state.  
 A glial cell with this breadth of diversity is thought to have strict innate mechanisms that 
modulate activation.  Similarly, a cell with the capability of adapting so readily to its environment is most 
likely highly sensitive to CNS aberrations, such as over-accumulation of amyloid-β or exposure to lead 
acetate, for example.  As stated earlier, a disrupted immune system early in development may have 
deleterious effects that persist throughout the individual’s lifetime, potentially causing 
hypersusceptibility to disease (Leifer and Dietert, 2011).  The neuroimmune system is not exempt from 
this potential impact of development immunotoxicant exposure.  Moreover, this early disruption could 
highlight and irritate the vulnerability that catalyzes AD pathogenesis.  Studies of early-life infection on 
cognitive decline have shown changes in glial markers, and potential aberrant glial responses later in life 
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(Bilbo, 2010).  Because of this we chose to analyze the microglial response, activation, and pathogenic 
role in our experimental design. 
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Figure 2. Morphological and phenotypic spectrum of microglial activation. (Karperien et al., 2013). 
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Figure 3. Diagram of the polarization of microglial activation states. M1, or classical activation, is 
considered pro-inflammatory, while M2, or alternative activation, is considered neuroprotective. Il-1β: 
interleukin 1-β; TNF-α: tumor necrosis factor-α; TGF-β: tumor growth factor-β; BDNF: bone-derived 
neurotrophic factor.  
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Interactions with Amyloid-β 
 The relationship between microglia and amyloid-β is far more entangled than a simple 
“phagocytizer” and “phagocytizee.”  There is substantial evidence showing microglial activation and 
association with oligomeric aβ, fibrillar aβ, and all senile plaque phenotypes (Cho et al., 2013; 
Koenigscknecht and Landreth, 2004; Combs et al., 2001; Stalder et al., 1999; Paresce et al., 1996).  The 
implication is that amyloid-β induces an activated microglial phenotype, directly or indirectly.  Microglia 
possess the ability to phagocytize aβ, but it is unclear if there is greater incidence of clearance, 
deposition, or lack of regulation in individuals with AD (Mawuenyega et al., 2010; Bolmont et al., 2008; 
Hickman et al., 2008; Cras et al., 1990).  We designed an experiment in which we disrupted the 
neuroimmune system and monitored subsequent changes to determine its role.  Our primary goal was 
to elucidate the role of a developmentally disrupted neuroimmune system in the exacerbation of AD 
pathologies.  With this in mind, we anticipate that the exposure to lead during a critical window of 
development for microglia would result in an altered immune system persisting in to adulthood, and a 
subsequent increase in the pathological severity of AD, as assessed by amyloid-β load and incidence, in a 
genetically prone murine model. 
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Chapter 2: 
Materials and Methods 
Animal Handling and Dosing 
 All animal handling, dosing, and euthanasia was carried out in accordance with procedures 
approved by the East Carolina University Brody School of Medicine Institutional Animal Care and Use 
Committee (IACUC).  Triple transgenic mice (3xTgAD) homozygous for all three mutations (B6;129-
Psen1tm1MpmTg(APPSwe,tauP301L)1Lfa/Mmjax) were used due to the spontaneous generation of 
Alzheimer’s-like plaque and tangle pathologies (Charles River, Raleigh, NC).  Transgenic mice were then 
paired for mating by the ECU Department of Comparative Medicine animal care staff and, once 
confirmed pregnant, dams were transferred to the Brody Animal Care Facility. On the day of birth, 
considered postnatal day one (PND1), pups were sexed and culled to six animals per dam, balanced by 
sex if possible.  All mice were maintained on a 12:12 hour light/dark cycle and fed and watered ad 
libitum.  If considered healthy following the 10 day dosing regimen, the neonates were weaned at 
PND21, placed into same sex cages of no more than three animals per cage with the appropriate 
enrichment, and monitored for signs of barbering and hydrocephaly.   
 Offspring were gavaged from PND5-15, a critical window of development for microglia in a 
rodent model.  Experimental dosing procedures were modified for neonate oral gavaging using a bent 
stainless steel 1.25mm 24G feeding needle with ball tip (ref# 7900, Braintree Scientific, Inc., Braintree, 
MA) and placed in the pup’s mouth to stimulate a suckling response rather than a potentially harmful 
full intubation.  Not only does this technique ensure consistency in dosing concentrations, but it is also a 
common practice in the laboratory that has been shown to provide a successful route of exposure in 
preweaning toxicity testing (Zoetis and Walls, 2005; Moser et al., 2005; Butchbach et al., 2007). 
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 The dosing solution consisted of either sterile water for control or lead (II) acetate (lot# 
MKBN8098V, Sigma-Aldrich, St. Louis, MO) dissolved in sterile water for treated animals.  The dosing 
concentration was set at a physiologically-relevant 100ppm, with 0.1mL dosing solution per 10g daily 
body weight, a concentration recommended in rodent model toxicity and risk assessment (Zoetis and 
Walls, 2005; Moser et al., 2005).  New batches of dosing solution were made each week.  Dams were 
euthanized at weaning (PND21), and pups were weighed and monitored daily until the predetermined 
terminal endpoint.  A total of 24 dams and 97 offspring were euthanized and assessed for pathological 
endpoints. 
Tissue Collection and Preparation 
 Three terminal endpoints were chosen, PND 50, 90, and 180. These endpoints were chosen 
based on the anticipated pathological detection of plaques and tangles for the 3xTgAD mouse model at 
approximately six months.  One neonate of each sex per litter, if available, was euthanized at the pre-
determined terminal endpoint.  Following decapitation a sagittal incision was made down the cranium, 
and the skull and meninges were carefully peeled back and away from the brain.  The full brain was 
carefully removed to avoid excess peripheral blood contamination.  We placed the tissue into a petri 
dish with phosphate buffered saline (PBS) and, using a coronal scalpel cut, removed the cerebellum and 
olfactory bulbs for consistency.  The two hippocampi were extracted using a novel technique to isolate 
the hippocampal regions CA1, CA3, and dentate gyrus (Hagihara et al., 2009).  Regardless of its 
hemispheric origin, one hippocampus was snap frozen at -800C for ELISA analysis.  The second 
hippocampus was placed directly in a scintillation vial filled with 10% neutral-buffered formalin for 24-
hour fixation, then placed in a tissue cassette submerged in 70% ethyl alcohol until subsequent 
embedding in paraffin wax.   
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 The formalin-fixed paraffin-embedded (FFPE) hippocampi were sliced on a rotary microtome at 
5m for offspring and 10m for dams, floated in warm water (~400C) and ethyl alcohol (50%) baths, and 
mounted on Unifrost Plus slides with Azerbond (cat #EMS600W+, Azer Scientific, Morgantown, PA), four 
sections per slide and four slides per animal.  Slides were left to dry overnight on a covered rack and 
stored in a slide box until IHC and IF staining.  Remaining brain tissue was immediately placed in buffer 
after hippocampal extraction to be homogenized for flow cytometric analysis. 
Enzyme-linked Imunosorbent Assay (ELISA) 
 To detect varying levels of the protein amyloid-β within the hippocampus, an enzyme-linked 
immunosorbent assay (ELISA) was performed on the snap frozen hippocampi.  The hippocampus was 
thawed, homogenized with phosphate buffered saline and tween (TPBS) in a 5mL Tenbroeck glass 
homogenizer, and weighed. A commercially available BetaMarkTM Beta Amyloid ELISA kit (cat #SIG-
38954-kit, Covance, Dedham, MA) as per manufacturer’s instructions, was used to assess protein 
concentrations.  Standard curve assessment and data analysis was carried out based on the absorbance 
readings obtained from the hippocampus samples and standards included in the ELISA kit. 
Flow Cytometry 
 Brain tissue sans hippocampi was homogenized in a 15mL Tenbroeck glass homogenizer 
containing FACS buffer (3% FCS + 0.1% sodium azide + 10 mM EDTA in PBS), passed through a 70m 
strainer, and centrifuged at 3000 RPM.  To remove myelin, the pellet was resuspended in 30% Percoll 
(#17-0891-02, GE Healthcare, Uppsala, Sweden), which has been shown to produce a higher yield of live 
cells in comparison to other demyelinating methods, e.g. sucrose and anti-myelin beads (Nikodemova 
and Watters, 2012).   
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After centrifugation at 3000 RPM, the supernatant containing the buoyant myelin and excess 
tissue debris was carefully removed via manual bulb suctioning with a 1mL glass pipette.  The 
subsequent pellet containing microglia was resuspended in buffer and passed through a 40m filter to 
produce a single-cell suspension and increase purity.  A third spin in the centrifuge (3000 RPM) and 
removal of the supernatant allowed for resuspension in the blocking buffer (FACS buffer + 5% normal 
mouse serum +5% normal rat serum + 1% Fcr block [polycloncal anti-mouse IgG CD16/CD32; stock #14-
0161, eBioscience, San Diego, CA]).  
Following another centrifugation/resuspension wash, the suspension was incubated with two 
monoclonal antibodies, CD11b-APC (1:100 dilution; ab25482, Abcam, Cambridge, MA) and CD45RB-FITC 
(1:100 dilution; cat# 11-0455-82, eBioscience Inc., San Diego, CA).  These surface antigens were chosen 
for their microglial specificity and consistent use throughout the literature (Sedgwick et al., 1991; Ford 
et al., 1995; Stevens et al., 2001; Parney et al., 2009; Nikodemova and Watters, 2012).  The antigen 
CD11 is a common surface marker for monocytes/macrophages, as well as microglia, which is why a 
second antigen was employed for immune specificity.  Microglia can take on a macrophage-like 
phenotype under certain conditions and function in a similar manner, which is why both have the 
surface antigen CD11.  However, CD45 is a leukocyte-common antigen and identifies cells with a myeloid 
lineage.  The degree to which microglia express these antigens has been associated with phenotypic 
changes that occur upon microglial activation (Stevens et al., 2001). 
After the dual-antibody incubation (one hour at 40C), another centrifugation/resuspension wash 
cycle was followed by propidium iodide (1 g/mL) live cell viability staining, and immediate analysis 
using a BD Accuri C6 flow cytometer (BD Biosciences, Franklin Lakes, NJ).  A total of 10,000 events were 
collected per sample and the emission wavelengths for each fluorophore were detected using the FL1 
(FITC) and FL4 (APC) lasers. Gating of the representative dot plots consisted of a consistent quadrant 
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marking scheme.  Analysis of microglial activation was performed through comparison of the ratio of the 
upper right quadrant (high expression of CD45/CD11b, activated microglia) to the lower left quadrant 
(low expression of CD45/CD11b, resting microglia).  
The flow cytometry dependent variable, “ratio,” was the value of the upper right (UR) quadrant 
of the flow output divided by the lower left (LL) quadrant value, meant to represent the number of 
activated (amoeboid) microglia (UR) corrected for ramified microglia and other macrophages (LL). 
Immunohistochemistry 
 Morphological changes associated with microglia activation were qualitatively assessed using 
immunostaining against the ionized calcium-binding adaptor molecule-1 (Iba1) surface antigens found 
on microglia.  The FFPE hippocampi tissue mounted on Superfrost Plus slides were dewaxed and 
rehydrated through sequential washing with Histo-Clear II (cat# 64111-04; Electron Microscopy 
Sciences, Halfield, PA), ethyl alcohol (100%, 95%), and PBS.  Antigen unmasking was accomplished using 
a heat-mediated citrate buffer system to break the protein cross-links generated during tissue fixation, 
improving antigen binding and specificity.  The slides were then submerged in 0.3% hydrogen peroxide 
for 30 minutes to quench endogenous peroxidases.  This reduces background staining by “capping” 
peroxidase inherently found on the cell surface so it cannot bind with the diaminobenzidine (DAB). 
 All immunostaining of the FFPE hippocampal slides was carried out using the Sequenza-
Coverplate system (Thermo Scientific, Waldorf, Germany), which combines surface tension, capillary 
attraction, and positive displacement to hold minimal amounts of reagent directly against the tissue 
without drying.  Slides were carefully pressed against Coverplates saturated in TPBS to eliminate air 
bubbles, and inserted into individual Sequenza slots.  All subsequent reagents were directly dispensed 
into the top of each slide well, ensuring consistency in staining quality with correct assembly.  Blocking 
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with diluted normal serum was followed by a 60 minute/overnight incubation with the primary 
antibody, rabbit polyclonal anti-Iba1 (1:500 dilution; stock #019-19741, Wako Chemicals USA, Inc., 
Richmond, VA).   
After incubation with the primary antibody, slides were washed with TPBS, and the biotinylated 
secondary antibody (diluted and prepared according to ABC Vectastain kit protocol) was applied for 30 
minutes.  The final labeling step was a biotinylated secondary antibody with an avidin peroxidase 
capable of oxidizing DAB for staining visualization.  Slides were then stained using a DAB kit (Vector 
Laboratories Inc., Burlington, ON, Canada) and counterstained with Harris’ Alum Hematoxylin (lot# 9290, 
Crescent Chemical Co., Inc., Islandia, NY).  Following removal from the Sequenza system, the slides 
underwent a final wash sequence of PBS, ethyl alcohol (95%, 100%), and Histoclear.  All slides were 
coverslipped with Permount (lot#107422, Fisher Scientific, Fair Lawn, NJ) and left to cure overnight prior 
to light microscopy visualization and manual morphometric analysis. 
The immunohistochemistry dependent variable, “IHCV,” was calculated by taking the number of 
amoeboid microglia per counting frame divided by the total microglia per frame, multiplied by the 
number of amoeboid microglia per frame, and multiplied again by the average total number of microglia 
for that particular sex, dose, and age group.  This arbitrary value was designed to give greater 
importance to amoeboid microglia, which are easier to detect via IHC than ramified microglia, and likely 
a more accurate representation of microglial activation. 
Immunofluorescence 
 Simultaneous imaging of both amyloid-β and microglia was accomplished through high-
resolution immunofluorescent staining and laser scanning confocal microscopy.  This method of 
visualization utilizes point-to-point laser scanning of the specimen, called optical sectioning, to create a 
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three dimensional image with incredibly high resolution and clarity to profile the overall surface, as well 
as interior structures. 
 The FFPE slides were dewaxed and rehydrated using the same HistoClear, ethyl alcohol (100%, 
95%), and PBS sequential wash as the IHC protocol.  Similarly, antigen unmasking occurred via heat-
mediated citrate buffer.  All subsequent immunofluorescent staining was carried out using the Sequenza 
plate system.  Sequenza coverplates were immersed in TPBS rather than PBS to promote membrane 
permeabilization and stripping of superfluous antibodies for optimal staining. 
 The complexities of staining with two primary and two secondary antibodies raised in separate 
hosts required strict sequential blocking wash steps (Table 1).  This system was created to ensure 
highest binding and specificity, while reducing self-adhesion to blocking proteins.  The first block (BW1) 
consisted of TPBS and donkey serum (10%), the host of the first secondary antibody.  After a 30 minute 
incubation at room temperature the first primary antibody, anti-Iba1 (1:1000 dilution; goat pAb to Iba1, 
ab107159, Abcam, Cambridge, MA), was applied for one hour, or overnight at 4oC if needed.  All 
following incubations occurred at room temperature removed from light due to the sensitivity of the 
secondary antibodies.  After a wash with TPBS, the slides were incubated for one hour with the first 
secondary antibody, anti-goat IgG-FITC (1:1000 dilution; donkey anti-goat FITC-conjugated polyclonal 
IgG, ab6881, Abcam, Cambridge, MA).  
 The second blocking wash (BW2), which consisted of TPBS, donkey serum (5%), and goat serum 
(30%), was applied for 30 minutes at room temperature, protected from light.  The following one hour 
incubation was with the second primary antibody, anti-beta amyloid (1:1000 dilution; rabbit pAb to beta 
Amyloid, ab2539, Abcam, Cambridge, MA).  After a wash with TPBS, there was a 30 minute incubation 
with the final secondary antibody, anti-rabbit IgG-Cy5 (1:1000 dilution; goat anti-rabbit Cy5-conjugated 
polyclonal IgG, ab97077, Abcam, Cambridge, MA).  Cell nuclei were stained using DAPI (300 nM dilution; 
28 
 
D3571, Life Technologies, Eugene, OR) for 2-5 minutes and washed three times with TPBS.  Following 
removal from the Sequenza racks the slides were left to dry completely before coverslipping with 
ProLong Gold antifade reagent (P36930, Life Technologies, Eugene, OR) or with a homemade anti-fade 
aqueous mounting media (glycerol, phosphate buffer solution-pH 7, and p-phenylenediamine 
hydrochloride).  For long term storage, edges of the slides were sealed with Permount if mounted with 
the homemade anti-fade media and stored upright in a slide box after curing. 
 Confocal viewing was performed with a Zeiss LSM 700 confocal microscope in the Brody Core 
Imaging Center.  The following emission wavelengths were used for tri-color visualization: DAPI – 
405nm, FITC – 488nm, and Cy5 – 639nm. All images were captured at 10x magnification, with the plaque 
counting frame of 640.17m by 640.17m.  Plaques were characterized based on number and relative 
morphology following a subjective scale guideline, shown in Figure 4. 
The immunofluorescence dependent variable, “ψ,” was calculated by multiplying the qualitative 
plaque scale value (1-5) by the intensity ratio (amyloid intensity bit value divided by 256 total bits) and 
again by the square root of the plaque area.  This arbitrary value was designed to assess the maturity of 
the plaque, taking into account the amyloid load and giving less importance to the plaque area, a less 
reliable aspect of plaque maturity based on the region of hippocampus analyzed and tissue thickness. 
Statistical Analysis 
 Analysis of all data was accomplished with the Statistical Analysis System (SAS Institute, Cary, 
NC).  Flow cytometry, immunohistochemistry, and immunofluorescence data were analyzed using a 
three-way analysis of variance (ANOVA) for differences in age, sex, and treatment (Flow, IF n=94; IHC 
n=337).  When appropriate, these were then followed by individual comparisons of differences between 
treated and control groups, as well as differences between sexes, using t-tests.  Post hoc analysis of 
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statistically significant differences in age, as determined by ANOVA, was accomplished using Tukey’s 
studentized range for equal variance and least squares means t-test for age-related differences.  ELISA 
data were analyzed for differences in age and treatment groups using t-tests assuming equal variance. P 
< 0.05 was considered significant.  
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Table 1. Immunofluorescence Staining Procedure. All dilutions 1:1000; Ab: antibody; TPBS: phosphate 
buffered saline with tween; IgG: immunoglobulin G. 
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Sequence Block Wash Primary Ab Host Secondary Ab Host 
Step 1 TPBS + donkey (10%) - - - - 
Step 2 TPBS Anti-Iba1 Goat - - 
Step 3  TPBS - - Anti-goat IgG Donkey 
Step 4 TPBS + donkey (5%) + goat (30%) - - - - 
Step 5 TPBS Anti-amyloid-β Rabbit - - 
Step 6 TPBS - - Anti-rabbit IgG Goat 
Step 7 TPBS [DAPI] - - - 
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Figure 4. Confocal images depicting qualitative senile plaque scale. Immunofluorescent images of the 
gradiation of senile plaques from least mature and diffuse (1) to most mature and cored (5).  Top row 
includes three fluorescent stains for microglia (green, FITC), amyloid-β (red, Cy5), and cell nuclei (blue, 
DAPI), with colocalization in yellow. Bottom row depicts the same image using only the 639 nm laser 
filter to illustrate amyloid load and variability with plaque maturation. Scale bar begins at 25 µm and 
gradually goes up to 75 µm. 
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Chapter 3: 
Results 
Flow Cytometry 
 There was no significant difference in microglia activation as detected by signaling of surface 
markers CD11b and CD45 among treatment, sex, and age through a three-way comparison of the UR:LL 
ratio means (Figure 5).  However, post hoc analysis showed lower microglial activation in treated 
females than control females at PND 180. General trends towards lower activation with age were 
observed for both sex and treatment. 
Immunohistochemistry 
 Phenotypic analysis of microglia activation via IHC showed significantly higher activation in 
treated animals at PND 50 (Figure 6).  There was also higher activation in control females than treated 
females at PND 90.  Post hoc analysis found higher activation in treated males than treated females at 
PND 50 and PND 90, and higher activation in control males than control females at PND 180. Overall, the 
age of the animal was important to microglial activation phenotypically, in regard to the exposure to 
lead; the older the animal the greater the phenotypic difference with both sex and treatment. 
Immunofluorescence 
 There were no significant differences in the pathological maturity of the plaques as assessed by 
IF (Figure 7).  More plaques were observed in treated than control males at PND 50 (Figure 8).  General 
trends revealed a slightly higher number of plaques in treated than control animals, and in treated 
males than treated females.  A typical, untreated 3xTgAD mouse developed plaques gradually, though 
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not necessarily by PND 50.  Treatment with lead, however, appeared to elicit more consistent incidence 
of plaque pathologies at all ages, even at the earliest terminal endpoint. 
ELISA 
 There was no significant difference in amyloid concentration, as detected by ELISA, among 
treatment, age, and sex (Figure 9).  General trends showed higher concentrations at the earlier time 
points (PND 50 and 90), and a drop at PND 180. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
Figure 5. 3xTgAD mouse brain microglial activation with age, sex, and treatment. Activation was 
assessed by the ratio of activated microglial surface markers CD11b and CD45 to ramified microglia 
(UR:LL) through flow cytometry.  Error bars as standard error.  Significant differences in treatment 
annotated by #. PND: postnatal day. 
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Figure 6. 3xTgAD mouse hippocampus microglial activation with age, sex, and treatment. Activation is 
assessed by the value “IHCV”, representing the number of amoeboid microglia with respect to overall 
number through morphometric analysis of phenotype via immunohistochemistry (microglia 
immnolabeled with anti-Iba1 antibodies).  Error bars as standard error.  Significant differences in 
treatment annotated by #. Significant differences in sex annotated by *. PND: postnatal day. 
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Figure 7. 3xTgAD mouse hippocampus senile plaque maturity with age, sex, and treatment. Activation is 
assessed by the value “ψ”, representing the overall maturity of the plaque, with respect to amyloid load, 
plaque size, and qualitative maturation analysis, via immunofluorescent labeling of microglia (anti-Iba1-
FITC), amyloid-β (anti-amyloidβ–Cy5), and cell nuclei (DAPI).  Error bars as standard error. PND: 
postnatal day. 
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Figure 8. 3xTgAD mouse hippocampus number of senile plaques with age, sex, and treatment. Plaques 
were visualized using immunofluorescent labeling of microglia (anti-Iba1-FITC), amyloid-β (anti-
amyloidβ–Cy5), and cell nuclei (DAPI). Error bars as standard error.  Significant differences in treatment 
annotated by #. PND: postnatal day. 
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Figure 9. 3xTgAD mouse hippocampus amyloid load with age, sex, and treatment. Amyloid load was 
assessed through aβ42 concentration using an enzyme-linked immunosorbent assay. Error bars as 
standard error. PND: postnatal day. 
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Chapter 4: 
Discussion 
 The primary goal of this study was to evaluate changes in Alzheimer’s pathology following 
developmental perturbation of the neuroimmune interface.  This approach allowed us to illuminate a 
potentially mechanistic role of the developing immune system in the etiology of a late-onset adult 
disease through an extensive array of immunological analyses within the confines of a defined set of 
experimental parameters.  Our study incorporated multifaceted approaches (i.e., flow cytometry, ELISA, 
immunohistochemistry, and immunofluorescence) to understand the interaction of microglia with AD 
pathologies and how this interaction could be disturbed by exposure to a developmental toxicant. 
 This experimental paradigm did not provide consistent results from assay to assay, nor was 
there a perfect linear correlation in lead-exposed mice between age and the severity of plaques.  We 
can, however, still draw interesting conclusions and suggest paths for future research.  The most striking 
significant difference was between treated and control groups in microglial morphology.  A greater 
number of amoeboid microglia were observed in the lead exposed group at PND 50, relative to 
unexposed groups.  However, in unexposed females evaluated at PND 90, more amoeboid microglia 
were observed.  These results suggest that exposure to lead acetate may be transient, i.e. it produces 
short-term changes that do not persist, or produces various downstream cascades that are detectable at 
later ages.  These differences can be explored, in part, by looking at the interrelation with the remaining 
independent variables, sex and age. 
 Both immunohistochemistry and flow cytometry were used to assess various aspects of 
microglial activation, which we then used as a gauge of an overall neuroimmune response.  We chose to 
exclude astrocytes, the only other glial cell type associated with senile plaques, as indicators of reactive 
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gliosis (a parallel CNS response to toxicants).  This exclusion was based on a study that demonstrated 
microglial activation both preceding and regulating subsequent astrocyte response to lead exposure 
(Zurich et al., 2002).  Thus, any alteration in microglia form, function, or activated phenotypic response 
would be indicative of early changes in the neuroimmune system.  Additional studies involving the same 
3xTgAD mouse model have shown no significant microglial activation (assessed via IHC) between 60 and 
180 day-old hippocampal sections (Janelsins et al., 2005).  This further validates the sensitivity of 
microglia as an indicator of neuroimmune response to a neurotoxicant, rather than the genetic disease 
state, whose amyloid pathologies have shown to be potent microglial activators (Combs et al., 2001). 
We chose to employ ELISA and immunofluorescence to measure changes in amyloid-β  
concentration and plaque involvement.  We then used these fluctuations in amyloid load to parallel 
overall AD pathological severity based on the catalytic theory of amyloid etiopathogenesis.  This is 
demonstrated by both the amyloid cascade hypothesis (Chapter 1), and the robust correlation of 
dementia in the elderly with traditional markers of protein accumulation, senile plaques, and related 
cytoskeletal changes (Dickson et al., 1995). 
Treatment-related Differences 
 The early “vulnerability” in Alzheimer’s disease pathogenesis we were attempting to highlight 
with our developmental exposure paradigm was temporally limited by critical windows of development 
for microglia.  We hypothesized the pathogenic weak spot was during this window of postnatal exposure 
(PND 5-15) for a variety of reasons.  First, microglia precursors are known to colonize the brain during 
embryonic and early postnatal stages, meaning these developing immune cells possess 
hypersusceptibility to environmental signals during this time frame, and were therefore more likely to 
be influenced by toxicant exposure (Pocock and Kettenmann, 2007).  Likewise, neurotoxicity of lead is 
maturationally-dependent, producing more intense glial reactions and aberrations in the neuronal 
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microenvironments in younger individuals (Zurich et al., 2002).  The focus on postnatal as opposed to 
prenatal exposure was twofold:  i) there appears to be a skew in the literature for analyzing prenatal 
exposure over postnatal, giving this study an innovative edge and, ii) a study by Koo et al. (2003) 
demonstrated that, while prenatal environment is pertinent to overall brain health, stress during this 
time can be corrected by postnatal conditions, implying that the postnatal environment has greater 
importance and ubiquity for neurodevelopment.   If there was a proverbial chink in the neuroimmune 
armor that could persist into adulthood, it would be during this critical window. 
Sex- and Age-related Differences 
 The incidence of Alzheimer’s disease is noticeably higher in women, who present with increased 
rate of cognitive decline and severity of dementia (Schmidt et al., 2008).  Heterochronic discord 
between the sexes also has been observed, with females developing pathologies faster and earlier than 
males, potentially due to age-related stress to the superior frontal gyrus transcriptome (Yuan et al., 
2012).  This skew is also thought to exist due to estrogen depletion later in life, rather than an early 
developmental or genetic vulnerability, which we investigated in this study.  Sexual discrepancy in the 
CNS is not a new concept.  In fact, sexual discrepancies can be seen in all aspects of our study, from the 
nervous and immune systems to overall development.  The oscillations in steroid hormones and gene 
expression may provide a critical developmental link in any pathological predilection towards a 
particular sex. 
 Male and female brains differ macroscopically, as well as microscopically (e.g. behavior and 
gene expression, respectively).  The differentiation extends to developmental timing as well.  
Investigations into related epigenetics indicate that these inherent differences are organized perinatally, 
and permanently influence adult behavior through myriad downstream cascades (Lenz et al., 2012).  
These post-genetic effects are conducted by the neuroimmune system.  Again, microglia demonstrate 
49 
 
their diversity by acting as vital components to the normal development and sexual differentiation of 
the brain.  Increased prevalence of activated phenotypes during development can be linked to the 
restructuring of neuronal circuits, axonal migration, and high levels of metabolism and metabolic 
signaling.  However, the number and activation of male microglia is higher during early postnatal 
development (PND 4), whereas female microglial activity crests later in development (PND 30-60) 
(Schwarz et al., 2012).  This suggests that male microglia may be more sensitive to exogenous influences 
than female microglia during our experimental exposure window.  Our data showed the gradual 
decrease in microglia activation from PND 50, when female activation is anticipated to be exceptionally 
high, to PND 180, when both sexes should, and do, show more relaxed and ramified phenotypes.  The 
trend over time was seen in the gradual decline in expression of activated surface markers (Fig. 5).  
 Immunohistochemistry illustrated a similar overall temporal decrease in immune response (Fig. 
6), but with a considerably weaker response in females at all terminal endpoints.  A wildtype control 
may have helped us to understand this phenomenon, but we hypothesize that the female response at 
PND 50 is accurate and normally elevated, and rather the difference is due to hyperstimulation of the 
male response due to the early immune disruption.  This idea is supported by the significant differences 
in sex-related activation only in animals exposed to lead (Fig. 6).  Likewise, there were sex differences 
between PND 50-90 and PND 50-180 activation surface markers in untreated brains and PND 50-90 for 
treated brains, but no differences in sex at the PND 180 time point.  Males that experienced an 
unperturbed activation crest and normal immune development exhibited the same gradual decline as 
control females.  We can expand our hypothesis to include a sexually dimorphic caveat: increased male 
microglial activation resulted from lead exposure, with a subsequent persistent immune response (i.e., 
activated microglia), and contributed to an increase in AD pathologies in male brains.  This counteracts 
the typical female skew in pathology, and reduces detectable sex differences in AD severity in our 
model.  This caveat is supported by the lack of significant differences in control male and female amyloid 
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load, as assessed by immunofluorescence (Fig. 7).  Thus, we can deduce that lead exposure had a 
greater activating effect on male microglia during this critical window of development. 
Immune Involvement in Early Stages of Disease 
 There were no significant differences in amyloid load as detected by ELISA and IF, but confocal 
imaging of cell nuclei, microglia, and amyloid-β reaffirmed the immediate involvement of the 
neuroimmune system at various stages of pathological progression.  The role of microglia in amyloid 
accumulation in AD pathology is not well-understood.  However, we were able to demonstrate the 
correlation of microglia with senile plaque formation through three dimensional immunofluorescent 
imaging (Fig. 10).  Some researchers argue this association with senile plaques is comparable to a 
massive clustering of dead cells and protein, as supported by the abnormal cell nuclei in the associated 
dystrophic neurites, rather than a counterattack from the active immune system (Streit 2010).  
Additionally, it has been proposed that axonal damage, synaptic dysfunction, and age-related neuronal 
death are the primary catalyst to amyloidosis, with microglia acting as a tardy and feeble attempt to 
clear the debris via phagocytosis, and are rapidly overwhelmed and dystrophic themselves (Streit et al., 
2009). 
 We propose a parallel hypothesis.  AD is a disease of the elderly, with much of the pathologies 
culminating from a perfect storm of normal age-related deficits and, occassionally, genetic influences.  
While searching for a fetal basis of adult disease and in attempt to elucidate a developmental immune 
vulnerability, we instead explored various potential targets, whose individual effects were not 
statistically significant.  If we subscribe to the theory that amyloid is not the sole catalyst for other 
pathologies then microglia, as processors of amyloid-β, become secondary and imply no immune 
component in etiopathogenesis.  However, microglia are the only immune cells intrinsic to the CNS, with 
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such an extensive array of functions, that there is a high probability that they are involved in the early 
exacerbation of neuronal dysfunction seen in AD individuals.   
Preceding selective neuronal loss, however, is the alteration of neurogenesis in the 
hippocampus (Lazarov and Marr, 2013).  The ACH returns yet again in the various studies that implicate 
APP fragments as having an amyloidogenic pathway and significant decreases in adult neuogenesis in 
murine models for AD, including our own (Mu and Gage 2011; Rodriguez et al., 2008; Donovan et al., 
2006).  Furthermore, this disturbed adult neurodegeneration has been propsed as the single neuronal 
vulnerability for early impaired cognition and decreased capacity for neuronal rebound (Schinder and 
Morganstern, 2009).  The cell type responsible for directing the development of neuronal circuits and 
proliferation of hippocampal progenitor cells is, of course, microglia.  So we have come full circle to re-
implicate the neuroimmune system in the early vulnerabilities for Alzheimer’s disease.   
We hypothesize that the early neuronal degeneration preceeding plaque and tangle pathologies 
is correlated to disturbances in the neuroimmune system, be it from abnormal development or age-
related microenvironmental stressors, such as calcium imbalances that occur in a typical aging 
paradigm.  Microglia have the capacity to undergo either neuroprotective or neurotrophic activation, 
which could occur in sequence or simultaneously, giving rise to the overt complexity of their role in AD.  
These activated microglia may then respond to distress signals from the dying neurons inappropriately, 
or transition to an inappropriate response due to improper signaling cues.  In a typical AD model, the 
microglia may become dystrophic themselves and fail to perform homeostatic functions, perturbing the 
delicate balance in the extracellular environment and promoting a positive apoptotic feedback loop.  In 
our own investigation, neuroimmune development was disturbed and may prematurely cause aberrant 
microglial responses, which would exacerbate the cascade of neuronal apoptosis and lack of proficient 
microglial responses. 
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We anticipate exploring the relationship of microglia with early neuronal degeneration in an AD 
model.  Future studies will attempt to determine the exact developmental mechanism and sexually 
dimorphic immune vulnerabilities to AD by utilizing a wildtype murine model for comparison.  Due to 
the early experimental time points and late pathological development, the terminal endpoints will be 
extended to ensure optimal visualization of any changes in pathologies.  Similarly, immunofluorescent 
studies will attempt to illustrate the early involvement of microglia in aberrant neurogenesis through 
visualization of progenitor cell colonization.  We anticipate these future studies will verify the seletive 
vulnerabilties in early neurimmune involvement in neurodegenerative diseases, as implied by the results 
of this study. 
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Figure 10. Immunofluorescent three color Z-stack imaging of a senile plaque in a treated male, PND 90. 
Microglia (green, FITC) are localized to the outer shell.  Cell nuclei (blue, DAPI) show abnormal shape and 
clustering, most likely depicting dystrophic neurites. Amyloid-β (red, Cy5) accumulation can be seen 
near the inner core of the plaque. 
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